Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

Company Overview - Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious degenerative genetic diseases [2] - The company utilizes its GeneTAC™ platform to create gene-targeted chimera small molecules that can modulate the expression of disease-causing genes [2] Product Development - The lead product, DT-216, is in development for Friedreich ataxia, with additional programs targeting Fuchs endothelial corneal dystrophy, Huntington's disease, and myotonic dystrophy type-1 [2] - Discovery efforts are ongoing for multiple genomic medicines [2] Upcoming Events - Management will participate in the 2024 Jefferies London Healthcare Conference on November 19, 2024, at 10:00 a.m. GMT in London, UK [1] - The company will also engage in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 11:30 a.m. ET in New York, NY [1] - Live webcasts of these presentations will be available and archived for at least 30 days [1]